Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Virani, Vijay Nambi, M. Razavi, V. Lee, M. Elayda, James Wilson, C. Ballantyne (2008)
Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery.American heart journal, 155 3
H. Nakamura, K. Arakawa, H. Itakura, A. Kitabatake, Y. Gotō, T. Toyota, N. Nakaya, Shoji Nishimoto, M. Muranaka, A. Yamamoto, K. Mizuno, Y. Ohashi (2006)
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trialThe Lancet, 368
P. Ridker, N. Rifai, M. Pfeffer, F. Sacks, E. Braunwald (1999)
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive ProteinCirculation, 100
J. Kjekshus, T. Pedersen, A. Olsson, O. Faergeman, K. Pyörälä (1997)
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.Journal of cardiac failure, 3 4
J. Shepherd, S.M. Cobbe, I. Ford (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med, 333
R. Shah, Yung Wang, J. Foody (2008)
Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.The American journal of cardiology, 101 2
M. Crisby, Gunilla Nordin-Fredriksson, P. Shah, J. Yano, Jenny Zhu, J. Nilsson (2001)
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque StabilizationCirculation: Journal of the American Heart Association, 103
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto, J. Kastelein, W. Koenig, P. Libby, A. Lorenzatti, Jean Macfadyen, B. Nordestgaard, J. Shepherd, J. Willerson, R. Glynn (2008)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.The New England journal of medicine, 359 21
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
Gissi-Hf Investigators (2008)
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 372
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto (2003)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 361
J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley, S. Cobbe, I. Ford, A. Gaw, M. Hyland, J. Jukema, A. Kamper, P. Macfarlane, A. Meinders, J. Norrie, C. Packard, I. Perry, D. Stott, Brian Sweeney, Gillian Twomey, R. Westendorp (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 360
J. Keddissi, Walid Younis, E. Chbeir, N. Daher, Tarek Dernaika, G. Kinasewitz (2007)
The use of statins and lung function in current and former smokers.Chest, 132 6
J. Halcox, J. Deanfield (2004)
Beyond the Laboratory: Clinical Implications for Statin PleiotropyCirculation: Journal of the American Heart Association, 109
S. Alexeeff, A. Litonjua, D. Sparrow, P. Vokonas, J. Schwartz (2007)
Statin use reduces decline in lung function: VA Normative Aging Study.American journal of respiratory and critical care medicine, 176 8
S. Rinfret, H. Behlouli, M. Eisenberg, K. Humphries, J. Tu, L. Pilote (2008)
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.American heart journal, 155 2
J. Ray, Y. Gong, K. Sykora, J. Tu (2005)
Statin use and survival outcomes in elderly patients with heart failure.Archives of internal medicine, 165 1
A. Go, Wendy Lee, Jingrong Yang, J. Lo, J. Gurwitz (2006)
Statin therapy and risks for death and hospitalization in chronic heart failure.JAMA, 296 17
R. Knopp, M. d’Emden, J. Smilde, S. Pocock (2006)
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 DiabetesDiabetes Care, 29
K. Wenke, B. Meiser, J. Thiery (2003)
Heart failure/transplant: abstractSimvastatin initiated early after heart transplantation: 8-year prospective experience☆Acc Current Journal Review, 12
Anil Verma, K. Ranganna, R. Reddy, Mandeep Verma, N. Gordon (2005)
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.The American journal of cardiology, 96 9
M. Tabata, Z. Khalpey, Paul Pirundini, M. Byrne, L. Cohn, J. Rawn (2007)
Renoprotective effect of preoperative statins in coronary artery bypass grafting.The American journal of cardiology, 100 3
H. Fukuta, D. Sane, S. Brucks, W. Little (2005)
Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary ReportCirculation, 112
F. Frost, H. Petersen, K. Tollestrup, B. Skipper (2007)
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.Chest, 131 4
G. Huhle, C. Abletshauser, N. Mayer, G. Weidinger, J. Harenberg, D. Heene (1999)
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.Thrombosis research, 95 5
G. Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, A. Montinaro (2009)
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.Journal of the American College of Cardiology, 54 6
Takahisa Yamada, K. Node, T. Mine, T. Morita, H. Kioka, Y. Tsukamoto, S. Tamaki, M. Masuda, K. Okuda, M. Fukunami (2007)
Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.American heart journal, 153 6
A. Beri, N. Sural, S.B. Mahajan (2009)
Non-atheroprotective effects of statins: a systematic reviewAm J Cardiovasc Drugs, 9
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen (2002)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).JAMA, 288 23
T. Anderson, I. Meredith, A. Yeung, B. Frei, A. Selwyn, P. Ganz (1995)
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.The New England journal of medicine, 332 8
P. Sever, B. Dahlöf, N. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 361
M. Takemoto, K. Node, H. Nakagami, Y. Liao, Michael Grimm, Yaeko Takemoto, M. Kitakaze, J. Liao (2001)
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.The Journal of clinical investigation, 108 10
Michelle Albert, J. Staggers, P. Chew, P. Ridker (2001)
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.American heart journal, 141 6
P. Ridker, N. Rifai, M. Clearfield, J. Downs, S. Weis, J. Miles, A. Gotto (2001)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.The New England journal of medicine, 344 26
C. Gibson, Yuri Pride, Claudia Hochberg, S. Sloan, M. Sabatine, Christopher Cannon (2009)
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.Journal of the American College of Cardiology, 54 24
C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 366
P. Ridker, N. Rifai, M. Pfeffer, F. Sacks, L. Moye, S. Goldman, G. Flaker, E. Braunwald (1998)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.Circulation, 98 9
G. Mancini, M. Etminan, Bin Zhang, L. Lévesque, J. FitzGerald, J. Brophy (2006)
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.Journal of the American College of Cardiology, 47 12
M. Dickinson, J. Ip, B. Olshansky, A. Hellkamp, Jill Anderson, J. Poole, D. Mark, Kerry Lee, G. Bardy (2007)
Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).American heart journal, 153 4
K. Khush, D. Waters, V. Bittner, P. Deedwania, J. Kastelein, S. Lewis, N. Wenger (2007)
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) StudyCirculation, 115
J. Deanfield, P. Sellier, E. Thaulow, J. Bultas, C. Yunis, H. Shi, J. Buch, B. Beckerman (2010)
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?European Heart Journal, 31
O. Schouten, N. Kok, E. Boersma, Jeroen Bax, H. Feringa, R. Vidaković, R. Eps, M. Sambeek, D. Poldermans (2006)
Effects of statins on renal function after aortic cross clamping during major vascular surgery.The American journal of cardiology, 97 9
A. Adabağ, D. Nelson, H. Bloomfield (2007)
Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure.American heart journal, 154 6
S. Mora, P. Ridker (2006)
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?The American journal of cardiology, 97 2A
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
P.M. Ridker, N. Rifai, M.A. Pfeffer (1999)
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) InvestigatorsCirculation, 100
T. Horwich, W. MacLellan, G. Fonarow (2003)
Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.Journal of the American College of Cardiology, 43 4
K. Wenke, B. Meiser, J. Thiery (2003)
Simvastatin initiated early after heart transplantation: 8-year prospective experienceCirculation, 107
J. Kjekshus, E. Apetrei, V. Barrios, M. Böhm, J. Cleland, J. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, L. Gullestad, Å. Hjalmarson, J. Hradec, A. Jánosi, G. Kamenský, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D. Veldhuisen, F. Waagstein, H. Wedel, J. Wikstrand (2007)
Rosuvastatin in older patients with systolic heart failure.The New England journal of medicine, 357 22
R.H. Knopp, M. D’Emden, J.G. Smilde (2006)
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)Diabetes Care, 29
P. Sever, N. Poulter, B. Dahlof, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Ostergren (2008)
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.European heart journal, 29 4
C. Briguori, G. Visconti, A. Focaccio, B. Golia, A. Chieffo, Alfredo Castelli, M. Mussardo, M. Montorfano, B. Ricciardelli, A. Colombo (2009)
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.Journal of the American College of Cardiology, 54 23
L. Biasucci, I. Porto (2010)
Has atorvastatin more than a DUAAL face?European heart journal, 31 21
J. Martínez-González, L. Badimón (2007)
Influence of statin use on endothelial function: from bench to clinics.Current pharmaceutical design, 13 17
Tsung-Ming Lee, T. Chou, Chang‐Her Tsai (2002)
Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2&agr; FormationJournal of Cardiovascular Pharmacology, 40
M. Shishehbor, S. Hazen (2009)
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Cleveland Clinic Journal of Medicine, 76
C. Treasure, J. Klein, W. Weintraub, J. Talley, M. Stillabower, A. Kosinski, Jian Zhang, S. Boccuzzi, J. Cedarholm, R. Alexander (1995)
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.The New England journal of medicine, 332 8
Abhimanyu Beri, Neethi Sural, Snigdha Mahajan (2009)
Non-Atheroprotective Effects of StatinsAmerican Journal of Cardiovascular Drugs, 9
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
R. Sukhija, Z. Bursac, Priyanka Kakar, L. Fink, C. Fort, Shiyam Satwani, W. Aronow, D. Bansal, J. Mehta (2008)
Effect of statins on the development of renal dysfunction.The American journal of cardiology, 101 7
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
G. O'Driscoll, D. Green, R. Taylor (1997)
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.Circulation, 95 5
J. Liao, U. Laufs (2005)
Pleiotropic effects of statins.Annual review of pharmacology and toxicology, 45
L. Hale, Karen Craver, Alan Berrier, Matthew Sheffield, L. Case, J. Owen (1998)
Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys.Arteriosclerosis, thrombosis, and vascular biology, 18 10
L. Fauchier, B. Pierre, A. Labriolle, C. Grimard, N. Zannad, D. Babuty (2008)
Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.Journal of the American College of Cardiology, 51 8
D. Walter, S. Dimmeler, A. Zeiher (2004)
Effects of statins on endothelium and endothelial progenitor cell recruitment.Seminars in vascular medicine, 4 4
H. Colhoun, D. Betteridge, P. Durrington, G. Hitman, H. Neil, S. Livingstone, M. Thomason, M. Mackness, V. Charlton-menys, J. Fuller (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 364
M. Domanski, S. Coady, J. Fleg, X. Tian, V. Sachdev (2007)
Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]).The American journal of cardiology, 99 10
G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA, 285
G. Schwartz, A. Olsson, M. Ezekowitz, P. Ganz, M. Oliver, D. Waters, A. Zeiher, B. Chaitman, S. Leslie, Theresa Stern (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.Indian heart journal, 53 2
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
M. Tonelli, C. Isles, T. Craven, A. Tonkin, M. Pfeffer, J. Shepherd, F. Sacks, C. Furberg, S. Cobbe, J. Simes, M. West, C. Packard, G. Curhan (2005)
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary DiseaseCirculation, 112
C. Maack, T. Kartes, H. Kilter, H. Schäfers, G. Nickenig, M. Böhm, U. Laufs (2003)
Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin TreatmentCirculation: Journal of the American Heart Association, 108
J. Brugts, T. Yetgin, S. Hoeks, A. Gotto, J. Shepherd, R. Westendorp, A. Craen, R. Knopp, H. Nakamura, P. Ridker, R. Domburg, J. Deckers (2009)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsThe BMJ, 338
D. Vidt, S. Harris, F. McTaggart, M. Ditmarsch, P. Sager, J. Sorof (2006)
Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.The American journal of cardiology, 97 11
Dalton Mclean, S. Ravid, M. Blazing, B. Gersh, A. Shui, C. Cannon (2008)
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.American heart journal, 155 2
K. Node, M. Fujita, M. Kitakaze, M. Hori, J. Liao (2003)
Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated CardiomyopathyCirculation: Journal of the American Heart Association, 108
Evidence is mounting that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have a number of pleiotropic effects over and above their lipid-lowering properties in patients with cardiovascular disease and heart failure. In addition to lowering low-density lipoprotein cholesterol and triglyceride levels, several studies have shown statins to improve survival and reduce the risk of major cardiovascular events in patients without established cardiovascular disease but with cardiovascular risk factors. Statins have also been shown to have beneficial effects, including a reduction in all-cause mortality, in patients with ischemic and non-ischemic congestive heart failure, and have been associated with a reduced incidence of atrial fibrillation. Furthermore, statins have been associated with improvements in renal function in patients with pre-existing renal disease or the prevention of new-onset renal dysfunction, as well as improvements in lung function in patients with chronic obstructive pulmonary disease or age-related decline in lung function. The pleiotropic effects of statins appear to result from improvements in endothelial function, a reduction in inflammatory mediators, a decline in the development of atheroma through the stabilization of atheromatous plaques, and the inhibition of cardiac hypertrophy through an antioxidant mechanism. Long-term statin use may reduce morbidity and mortality rates in a broad range of patients, and most patients at high risk of cardiovascular disease may benefit from statin treatment; however, further data are required to demonstrate conclusively whether these trends are truly independent of the lipid-lowering effects of statins.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Oct 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.